Date: Jul 01, 2010 Source: pharmamedtechbi.com
In an all-stock deal, Marina Biotech (RNAi therapeutics) has purchased the intellectual property related to Novosom AG's Smarticles platform, a liposomal-based drug delivery system, which Marina will use for systemic and local administration of its UsiRNA therapeutics. The Smarticles assets include 42 issued or allowed patents and 31 pending patent applications covering liposomal delivery formulations, lipid compounds, and nucleic acid chemistry
